Study to Evaluate the Safety of MEDI-534 Vaccine Against Respiratory Syncytial Virus (RSV) and Parainfluenza Virus Type 3 (PIV3) in Healthy Children

PHASE1CompletedINTERVENTIONAL
Enrollment

120

Participants

Timeline

Start Date

June 30, 2006

Study Completion Date

May 31, 2007

Conditions
Healthy
Interventions
BIOLOGICAL

MEDI-534

10:4 TCID50 of MEDI-534 intranasal spray Study Day 0

BIOLOGICAL

MEDI-534

10:5 TCID50 of MEDI-534 intranasal spray Study Day 0

BIOLOGICAL

MEDI-534

10:6 TCID50 of MEDI-534; intranasal spray

Trial Locations (12)

10467

Children's Hospital at Montefiore; Montefiore Medical Center, The Bronx

13901

Regional Clinical Research, Inc., Binghamton

15241

Primary Physicians Research, Inc., Pittsburgh

21201

University of Maryland Pediatric Ambulatory Center, Baltimore

40004

Kentucky Pediatric/Adult Research, Bardstown

41017

Cincinnati Children's Hospital Medical Center, Division of Infectious Disease, Crestview Hills

45245

Pediatric Associates of Mt. Carmel, Inc., Cincinnati

66216

Heart of America Research, Shawnee

66614

Heart of America Research, Topeka

68134

Meridian Clinical Research, LLC, Omaha

92708

Edinger Medical Group, Fountain Valley

25701-3655

University Physicians Internal Medicine, Huntington

Sponsors

Lead Sponsor

All Listed Sponsors
lead

MedImmune LLC

INDUSTRY